Abstract
Chronic kidney disease and especially end-stage renal disease (ESRD) are regularly associated with profound disturbances in the mineral metabolism characterized by secondary hyperparathyroidism (SHPT), hyperphosphatemia, hypercalcemia, elevated calcium-phosphorus product and renal osteodystrophy. These metabolic changes are either the result of the disease itself or due to toxicity from current therapeutic options. There is growing evidence that besides the classical cardiovascular risk factors, non-traditional uremia-specific risk factors, including abnormal mineral metabolism and SHPT, play a key role in the excessively increased cardiovascular mortality and morbidity in these patients. Calcimimetics represent an innovative new therapeutic compound in the treatment of SHPT, acting as allosteric activators of the calcium-sensing receptor. In this review we will discuss the consequences of SHPT in ESRD patients on vascular calcification, its impact on cardiovascular morbidity and mortality and the potential role of calcimimetics in preventing the cardiovascular consequences of SHPT.
Keywords: Calcimimetics, cinacalcet, secondary hyperparathyroidism, vascular calcification, cardiovascular disease, endstage renal disease (ESRD)
Current Drug Therapy
Title: Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular Mortality: Potential Benefit of Calcimimetics
Volume: 1 Issue: 2
Author(s): Emanuel Zitt and Alexander R. Rosenkranz
Affiliation:
Keywords: Calcimimetics, cinacalcet, secondary hyperparathyroidism, vascular calcification, cardiovascular disease, endstage renal disease (ESRD)
Abstract: Chronic kidney disease and especially end-stage renal disease (ESRD) are regularly associated with profound disturbances in the mineral metabolism characterized by secondary hyperparathyroidism (SHPT), hyperphosphatemia, hypercalcemia, elevated calcium-phosphorus product and renal osteodystrophy. These metabolic changes are either the result of the disease itself or due to toxicity from current therapeutic options. There is growing evidence that besides the classical cardiovascular risk factors, non-traditional uremia-specific risk factors, including abnormal mineral metabolism and SHPT, play a key role in the excessively increased cardiovascular mortality and morbidity in these patients. Calcimimetics represent an innovative new therapeutic compound in the treatment of SHPT, acting as allosteric activators of the calcium-sensing receptor. In this review we will discuss the consequences of SHPT in ESRD patients on vascular calcification, its impact on cardiovascular morbidity and mortality and the potential role of calcimimetics in preventing the cardiovascular consequences of SHPT.
Export Options
About this article
Cite this article as:
Zitt Emanuel and Rosenkranz R. Alexander, Consequences of Secondary Hyperparathyroidism on Vascular Calcification and Cardiovascular Mortality: Potential Benefit of Calcimimetics, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776931012
DOI https://dx.doi.org/10.2174/157488506776931012 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology Mitochondria-Targeted Antioxidant Peptide SS31 Protects the Retinas of Diabetic Rats
Current Molecular Medicine Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Molecular Mechanisms of Restenosis After Percutaneous Peripheral Angioplasty and Approach to Endovascular Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Determination of Isoflavones in Legumes by QuEChERS-Capillary Electrophoresis-Electrospray Ionization-Mass Spectrometry
Current Analytical Chemistry Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research The Inhibitory Effect of Some Algerian Plants Phenolics Extracts on the α - glucosidase and α - amylase Activities and their Antioxidant Activities
Current Enzyme Inhibition Circulating Endothelial Cells: Markers and Mediators of Vascular Damage
Current Stem Cell Research & Therapy Editorial [Hot topic: Transportalopathy and Vascular Cell Dysfunction (Guest Editor: Luis Sobrevia)]
Current Vascular Pharmacology Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Biomarkers of Oxidative Stress and the Relationship to Cigarette Smoking
Mini-Reviews in Organic Chemistry Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Novel Strategies for Preventing Diabetes and Obesity Complications with Natural Polyphenols
Current Medicinal Chemistry Alkaptonuria, Ochronosis and Ochronotic Arthropathy in Mainland France and the Reunion Island. A Report of Clinical and Molecular Findings in 29 Patients
Current Rheumatology Reviews Diacylglycerol Kinase Inhibition and Vascular Function
Current Enzyme Inhibition Renal Endothelial Dysfunction in Diabetic Nephropathy
Cardiovascular & Hematological Disorders-Drug Targets Amniotic Fluid Embolism: What Level of Scientific Evidence can be Drawn? A Systematic Review
Current Pharmaceutical Biotechnology Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design
Current Rheumatology Reviews